Antihypertensive treatment and risk of cardiovascular complications: Is the cure worse than the disease?

Journal of Hypertension

Volumn 27, Issue 2, 2009, Pages 221-223

  Ibsen, Hans ^a  

^a HOLBÆK HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; METOPROLOL; NEBIVOLOL; THIAZIDE DIURETIC AGENT;

ANTIHYPERTENSIVE THERAPY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DRUG USE; HUMAN; HYPERTENSION; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK BENEFIT ANALYSIS; RISK REDUCTION; STROKE; BLOOD PRESSURE; COMORBIDITY; RISK FACTOR;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; COMORBIDITY; HUMANS; HYPERTENSION; RISK FACTORS;

EID: 63849136144     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32831e9962     Document Type: Note

References (28)

1. Mancia G, De Backer G, Dominiczak A, et al. Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25:1105-1187.
2. Lindholm L, Ejlertsson G, Scherste'n B. High risk of cerebro- cardiovascular morbidity in well treated male hypertensives. A retrospective study of 40-59-year-old hypertensives in a Swedish primary care district. Acta Med Scand 1984; 216:251-259.
3. Thü rmer HL, Lund-Larsen PG, Tverdal A. Is blood pressure treatment as effective in a population setting as in controlled trials? Results from a prospective study. J Hypertens 1994; 12:481-490.
4. Clausen J, Jensen G. Blood pressure and mortality: an epidemiological survey with 10 years follow-up. J Hum Hypertens 1992; 6:53-59.
5. Andersson OK, Almgren T, Persson B, et al. Survival in treated hypertension: follow up study after two decades. BMJ 1998; 317: 167-171.
6. Almgren T, Persson B, Wilhelmsen L, et al. Stroke and coronary heart disease in treated hypertension: a prospective cohort study over three decades. J Intern Med 2005; 257:496-502.
7. Bulpitt CJ. Is blood pressure treatment as effective in a population setting as in controlled risk? Results from a prospective study. J Hypertens 1994; 12:987-988.
8. Thelle DS. Is blood pressure treatment as effective in a population setting as in controlled trials? Results from a prospective study. J Hypertens 1995; 13:567-569.
9. Benetos A, Thomas F, Bean KE, et al. Why cardiovascular mortality is higher in treated hypertensives versus subjects of the same age, in the general population. J Hypertens 2003; 21:1635-1640.
10. Li C, Engström G, Hedblad B, Berglund G, et al. Blood pressure control and risk of stroke: a population-based prospective cohort study. Stroke 2005; 36:725-730.
11. Klungel OH, Stricker BH, Breteler MM, et al. Is drug treatment of hypertension in clinical practice as effective as in randomized controlled trials with regard to the reduction of the incidence of stroke? Epidemiology 2001; 12:339-344.
12. Grobbee DE, Hoes AW. Confounding and indication for treatment in evaluation of drug treatment for hypertension. BMJ 1997; 315:1151- 1154.
13. Asayama K, Ohkubo T. Yoshida S, Suziki K, Metoki H, Harada A, et al. Stroke risk and antihypertensive drug treatment in the general population: the Japan Arteriosclerosis Longitudinal Study (JALS). J Hypertens 2009 (in press).
14. Williams B. Recent hypertension trials: implications and controversies. J Am Coll Cardiol 2005; 45:813-827.
15. Lewington S, Clarke R, Qizilbash N, et al. Prospective Studies CollaborAge-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360:1903-1913.
16. Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005; 366:1545-1553.
17. Messerli FH, Grossman E, Goldbourt U. Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. JAMA 1998; 279:1903-1907.
18. Alderman MH. New onset diabetes during antihypertensive therapy. Am J Hypertens 2008; 21:493-499.
19. Verdecchia P, Reboldi G, Angeli F, et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 2004; 43:963-969.
20. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288:2981-2997.
21. Psaty BM, Smith NL, Siscovick DS, et al. Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. JAMA 1997; 277:739-745.
22. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363:2022-2031.
23. Dahlö f B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366:895-906.
24. Kaplan NM. Recent clinical trials: the good, the bad, and the misleading. Hypertension 2008; 52:608-609.
25. Messerli FH, Williams B, Ritz E. Essential hypertension. Lancet 2007; 370:591-603.
26. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive bloodpressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351:1755-1762.
27. Kjeldsen SE, Jamerson KA, Bakris GL, et al. Avoiding cardiovascular events through combination therapy in patients living with systolic hypertension. Predictors of blood pressure response to intensified and fixed combination treatment of hypertension: the ACCOMPLISH study. Blood Press 2008; 17:7-17.
28. Ibsen H,Olsen MH, Wachtell K, et al. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension 2005; 45:198-202.